Overview

Safety and Efficacy of SPARC1203 in Allergic Rhinitis

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This study will assess safety and efficacy of SPARC1203 delivered via nasal spray in patients with allergic rhinitis
Phase:
Phase 2
Details
Lead Sponsor:
Sun Pharma Advanced Research Company Limited